Osteosarcoma Conventional treatment vs. gene therapy

被引：91
作者：
Tan, Mei Lin [1 ,2 ]
Choong, Peter F. M. [1 ,2 ,3 ]
Dass, Crispin R. [1 ,2 ]
机构：
[1] Univ Melbourne, St Vincents Hosp Melbourne, Dept Orthopaed, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, St Vincents Hosp Melbourne, Dept Surg, Fitzroy, Vic 3065, Australia
[3] Peter MacCallum Canc Inst, Bone & Soft Tissue Sarcoma Serv, Melbourne, Vic 3000, Australia
来源：
CANCER BIOLOGY & THERAPY | 2009年 / 8卷 / 02期
关键词：
osteosarcoma; treatment; gene therapy; surgery; chemotherapy; radiotherapy; EPITHELIUM-DERIVED FACTOR; CHITOSAN-DNA NANOPARTICLES; HIGH-GRADE OSTEOSARCOMA; HIGH-DOSE METHOTREXATE; SMALL INTERFERING RNA; IN-VIVO; ANTHRACYCLINE CARDIOTOXICITY; OLIGONUCLEOTIDE DELIVERY; COMBINATION CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY;
D O I：
10.4161/cbt.8.2.7385
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Osteosarcoma (OS) remains the most common primary malignant bone cancer affecting children and adolescents. Majority of patients are subjected to surgery and chemotherapy with limited alternatives to consider. However, with increasing knowledge of the molecular pathogenesis of OS, advancements in OS therapy research fields have developed potential agents for a more targeted and localised approach to treatment. Thus, this review attempts to examine some common treatment strategies (surgery, radiotherapy and chemotherapy) employed clinically as well as recent developments in newer experimental therapy methods (gene therapy) which might potentially benefit patients.
引用
收藏
页码：106 / 117
页数：12
相关论文
共 156 条
[1]   Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients [J].
Andersen, A ;
Holte, H ;
Slordal, L .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (05) :422-426
[2]  
[Anonymous], PHASE 3 RANDOMIZED S
[3]  
AVELLA M, 1998, CHEMOPTERAPIA, V7, P133
[4]   Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli Osteosarcoma-2 protocol: An updated report [J].
Bacci, G ;
Ferrari, S ;
Bertoni, F ;
Ruggieri, P ;
Picci, P ;
Longhi, A ;
Casadei, R ;
Fabbri, N ;
Forni, C ;
Versari, M ;
Campanacci, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4016-4027
[5]   High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian sarcoma group/Scandinavian sarcoma group pilot study [J].
Bacci, G ;
Ferrari, S ;
Longhi, A ;
Picci, P ;
Mercuri, M ;
Alvegard, TA ;
Saeter, G ;
Donati, D ;
Manfrini, M ;
Lari, S ;
Briccoli, A ;
Forni, C .
JOURNAL OF CHEMOTHERAPY, 2002, 14 (02) :198-206
[6]   Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years - Outcome in 34 cases treated with Adriamycin, Cisplatinum and Ifosfamide between 1984 and 1999 [J].
Bacci, Gaetano ;
Ferrari, Stefano ;
Mercuri, Mario ;
Longhi, Alessandra ;
Fabbri, Nicola ;
Galletti, Stefano ;
Forni, Cristiana ;
Balladelli, Alba ;
Serra, Massimo ;
Picci, Piero .
ACTA ORTHOPAEDICA, 2007, 78 (03) :377-384
[7]   A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas [J].
Basaran, Mert ;
Bavbek, E. Sevil ;
Saglam, Sezer ;
Eralp, Levent ;
Sakar, Burak ;
Atalar, Ata Can ;
Bilgic, Bilge ;
Ozger, Harzem ;
Onat, Haluk .
ONCOLOGY, 2007, 72 (3-4) :255-260
[8]  
Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO
[9]  
2-D
[10]   Brothers in arms - DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies [J].
Bhindi, Ravinay ;
Fahmy, Roger G. ;
Lowe, Harry C. ;
Chesterman, Colin N. ;
Dass, Crispin R. ;
Cairns, Murray J. ;
Saravolac, Edward G. ;
Sun, Lun-Quan ;
Khachigian, Levon M. .
AMERICAN JOURNAL OF PATHOLOGY, 2007, 171 (04) :1079-1088
12345678910